HS
HighVista Strategies Portfolio holdings
AUM
$272M
1-Year Return
24.34%
This Quarter Return
+16.91%
1 Year Return
+24.34%
3 Year Return
+176.43%
5 Year Return
+271.23%
10 Year Return
+682.63%
AUM
$276M
AUM Growth
+$59.5M
(+28%)
Cap. Flow
+$45.5M
Cap. Flow
% of AUM
16.5%
Top 10 Holdings %
Top 10 Hldgs %
29.49%
Holding
157
New
25
Increased
65
Reduced
12
Closed
31
Top Buys
| 1 |
Spyre Therapeutics
SYRE
|
$12.4M |
| 2 |
HES
Hess
HES
|
$4.17M |
| 3 |
SOVO
Sovos Brands, Inc. Common Stock
SOVO
|
$4.07M |
| 4 |
SP
SP Plus Corporation
SP
|
$4.04M |
| 5 |
UiPath
PATH
|
$3.07M |
Top Sells
Sector Composition
| 1 | Healthcare | 45.71% |
| 2 | Technology | 11.75% |
| 3 | Consumer Discretionary | 6.51% |
| 4 | Industrials | 5.31% |
| 5 | Consumer Staples | 4.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Autoliv
ALV
$9.56B
| $798K | 0.29% |
7,244
+2,000
| +38% | +$220K |
|
102
Nu Holdings
NU
$70.4B
| $779K | 0.28% |
+93,461
| New | +$779K |
|
103
Alibaba
BABA
$312B
| $764K | 0.28% |
9,857
+2,900
| +42% | +$225K |
|
|
ALPN
104
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $760K | 0.28% |
39,861
| – | – |
|
|
ITCI
105
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $684K | 0.25% |
9,545
| – | – |
|
106
Rhythm Pharmaceuticals
RYTM
$6.91B
| $660K | 0.24% |
+14,362
| New | +$660K |
|
107
Protagonist Therapeutics
PTGX
$3.61B
| $650K | 0.24% |
+28,359
| New | +$650K |
|
108
Revolution Medicines
RVMD
$7.32B
| $650K | 0.24% |
22,650
+4,645
| +26% | +$133K |
|
|
VRNA
109
Verona Pharma
VRNA
$9.18B
| $645K | 0.23% |
32,449
+2,576
| +9% | +$51.2K |
|
110
TAL Education Group
TAL
$6.25B
| $619K | 0.22% |
49,000
-1,300
| -3% | -$16.4K |
|
111
Roivant Sciences
ROIV
$8.78B
| $617K | 0.22% |
+54,930
| New | +$617K |
|
112
Pliant Therapeutics
PLRX
$99.4M
| $616K | 0.22% |
34,039
+3,316
| +11% | +$60.1K |
|
113
Vaxcyte
PCVX
$4.04B
| $585K | 0.21% |
9,321
-1,927
| -17% | -$121K |
|
114
Crinetics Pharmaceuticals
CRNX
$3.18B
| $566K | 0.21% |
+15,899
| New | +$566K |
|
115
Galapagos
GLPG
$2.04B
| $527K | 0.19% |
12,953
-694
| -5% | -$28.2K |
|
116
New Oriental
EDU
$7.98B
| $520K | 0.19% |
7,100
+700
| +11% | +$51.3K |
|
117
Geron
GERN
$900M
| $507K | 0.18% |
240,234
+39,341
| +20% | +$83K |
|
118
United Therapeutics
UTHR
$17.4B
| $506K | 0.18% |
2,299
| – | – |
|
119
Couchbase
BASE
$1.35B
| $413K | 0.15% |
+18,326
| New | +$413K |
|
120
argenx
ARGX
$45.2B
| $406K | 0.15% |
1,067
| – | – |
|
121
Amylyx Pharmaceuticals
AMLX
$875M
| $388K | 0.14% |
26,349
| – | – |
|
122
Ascendis Pharma
ASND
$12.2B
| $356K | 0.13% |
2,828
-3,070
| -52% | -$387K |
|
123
Li Auto
LI
$24.6B
| $336K | 0.12% |
8,966
| – | – |
|
124
Madrigal Pharmaceuticals
MDGL
$9.59B
| $331K | 0.12% |
1,431
-1,614
| -53% | -$373K |
|
125
Udemy
UDMY
$994M
| $272K | 0.1% |
+18,497
| New | +$272K |
|